News

FDA official restricted COVID vaccine approvals against staff advice
The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally ...
Infectious Disease Advisor1h
Multicomponent Vaccine for COVID-19, Influenza Shows Promise in Phase 3 Trial
The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.
Investor's Business Daily on MSN1h
Robert F. Kennedy Jr. Just Did The Unexpected. He Helped Moderna.
Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.
Renal & Urology News2h
Moderna’s New Flu Shot Shows Strong Results in Older Adults
The new results helped boost Moderna’s stock by more than 4% in early trading Monday, though the company’s shares are still down about 32% for the year. Moderna has more on the science behind mRNA.
Zacks Investment Research on MSN2h
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...
Moderna says mRNA flu vaccine sailed through trial, beating standard shot
Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...
Experimental Moderna flu shot more effective than approved vaccine, company says
Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the Centers for Disease Control and Prevention.